KNSA vs REGN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

REGN is the larger of the two ($96.28B market cap): the incumbent the market prices for continued execution (12.99x forward earnings, beta 0.09). KNSA is the smaller challenger ($7.39B), actually pricier on forward earnings (46.00x): more room to run, but more to prove. If you believe in growth, KNSA fits: analysts expect its revenue to rise 28% next year, against 7% for REGN. If you believe in paying less for profit, REGN fits: it trades at 12.99x forward earnings, against 46x for KNSA.

KNSA vs REGN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricKNSAREGNWhat it tells you
Market cap$7.39B$96.28BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E46.0012.99Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E71.2720.57Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.080.09Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range92% of range85% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book10.402.79How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: REGN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how KNSA and REGN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. KNSA and REGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined KNSA and REGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Kiniksa Pharmaceuticals (KNSA) do?

Kiniksa Pharmaceuticals (Nasdaq: KNSA) is a commercial-stage biopharmaceutical company focused on immune-modulating and cardiovascular therapies. Its franchise is ARCALYST (rilonacept), an IL-1 blocker approved for recurrent pericarditis (a painful inflammatory condition of the heart lining) that it commercializes in the US under a collaboration with Regeneron. ARCALYST drove roughly $677.5 million of net product revenue in 2025, up about 62% from 2024. Growth kept accelerating in 2026: revenue was roughly $214.3 million in Q1 (up about 56% year over year), $243.6 million in Q2 (up about 55%) and about $286 million in Q3 (up about 58%), and management has raised full-year 2026 net product revenue guidance three times, most recently to $1.045 to $1.050 billion. About 5,450 clinicians had prescribed ARCALYST by the end of Q3, roughly 450 more than a quarter earlier, and management estimates it has reached about 23% of the roughly 14,000-patient multiple-recurrence population.

Full KNSA guide

What does Regeneron Pharmaceuticals (REGN) do?

Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base. Total revenue then stepped up to about $4.29 billion in Q2 2026, up roughly 17% year over year, and to about $5.12 billion in Q3 2026, up roughly 36%, taking trailing twelve-month revenue to about $16.9 billion and net income to about $4.8 billion. Quarterly net income rose from about $727 million in Q1 to about $1.3 billion in Q2 and about $1.95 billion in Q3.

Full REGN guide

KNSA vs REGN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • KNSA drivers: ARCALYST adoption in recurrent pericarditis; Profitable growth profile.
  • REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is single-product concentration: essentially all revenue depends on ARCALYST in one indication, so any competitive entry, reimbursement pressure, safety signal, or eventual loss of exclusivity would be material. For REGN, the clearest risk is Eylea biosimilar erosion.

KNSA or REGN: which should you pick?

If the story you believe is KNSA's (ARCALYST adoption in recurrent pericarditis), KNSA is the more direct way to own it; if it is REGN's (Dupixent keeps compounding), REGN is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the KNSA and REGN guides.

KNSA vs REGN: the full fundamentals

KNSA. As of November 2026, Kiniksa carried a market cap of roughly $7.4 billion against trailing revenue near $946 million and net income around $110 million, for a trailing P/E near 71. That multiple reflects both rare biotech profitability and expectations that ARCALYST keeps compounding past the raised 2026 guidance and that analysts' forecast of about $1.35 billion of 2027 revenue and $2.05 of EPS holds. The seven analysts in Yahoo's count rate it a strong buy with a mean target near $112, and the stock is up about 124% in 2026.

REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron has beaten EPS estimates in each of the last five quarters, most sharply in Q2 and Q3 2026 (about $20.07 against $16.25 in Q3), and the shares rose about 15.5% over the past month to roughly $930, up about 26% over a year. Consensus for Q4 2026 sits near $25.80 of EPS on about $5.85 billion of revenue, but 2027 EPS is forecast lower at about $62, and the ~13x forward P/E reflects the market weighing strong Dupixent growth and new launches against Eylea biosimilar erosion. After Q3, Argus lifted its target to $1,050 and Goldman Sachs to $1,115, with a 27-analyst mean near $991.

Headline figures (approximate, November 2026): KNSA shows revenue (ttm) ~$946M, q3 2026 revenue ~$286M (up ~58% YoY), net income (ttm) ~$110M (EPS ~$1.32), margins (ttm) ~54% gross, ~14% operating, ~12% net; REGN shows total revenue (ttm) ~$16.9 billion, q3 2026 total revenue ~$5.12 billion (up ~36% YoY), q3 2026 eps vs estimate ~$20.07 vs ~$16.25, net income (ttm) ~$4.8 billion (~29% net margin).

The bottom line: KNSA vs REGN

KNSA and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined KNSA and REGN exposure against your real portfolio. It is not an investment adviser.

Wondering how KNSA or REGN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Kiniksa Pharmaceuticals

Ask Walnut's AI anything about KNSA and see how it fits what you own.

FAQ

What is the difference between KNSA and REGN?

+

Kiniksa Pharmaceuticals (Nasdaq: KNSA) is a commercial-stage biopharmaceutical company focused on immune-modulating and cardiovascular therapies. Regeneron makes money primarily through two large franchises. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is KNSA or REGN the better stock?

+

Neither is universally better. REGN is the larger incumbent; KNSA is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, KNSA or REGN?

+

On forward P/E (as of November 2026), KNSA trades at 46.00x and REGN at 12.99x, so REGN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both KNSA and REGN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of KNSA vs REGN?

+

KNSA: The dominant risk is single-product concentration: essentially all revenue depends on ARCALYST in one indication, so any competitive entry, reimbursement pressure, safety signal, or eventual loss of exclusivity would be material. The stock trades at about 71 times trailing and 46 times forward earnings after more than doubling over the past year, so a growth deceleration or a guidance miss could compress the valuation sharply; quarterly EPS missed estimates in late 2025 even as revenue grew. Insiders sold several blocks of shares in November 2026 after the rally. The pipeline remains binary: a PASTORALE failure, with data expected in the second half of 2027, would remove the main franchise-extension thesis, and KPL-1161 has not yet entered the clinic. ARCALYST is co-developed with Regeneron, so collaboration economics and terms matter to Kiniksa's share of profits. As a small-cap biotech, the shares are volatile and sensitive to single data readouts. REGN: The clearest risk is Eylea biosimilar erosion. Amgen's Pavblu launched in late 2024 and pressured sales, and settlements clear paths for Sandoz, and Alvotech and Teva, to launch competing copies in the U.S. around the fourth quarter of 2026, with erosion expected to accelerate. Eylea HD and Dupixent growth are the offsets, but the timing gap matters. The market is also pricing a peak: consensus sees 2026 EPS near $69 and 2027 EPS near $62 even as revenue is forecast to rise to about $20.2 billion, so recent beats raise the bar rather than reset it, and the shares have run about 20% this year to near the top of their 52-week range. The business is also concentrated in a few franchises, so a single setback in Dupixent or a major pipeline failure would weigh heavily, and the collaboration structure with Sanofi means Regeneron does not control all of its largest product's economics. Livsayis carries a boxed warning for serious meningococcal infections and a restricted REMS program, which can slow uptake of a new launch.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell KNSA or REGN; figures are approximate and dated (as of November 2026). Verify current data before investing.